Active Ingredient(s): Gadopentetate
FDA Approved: * June 2, 1988
Pharm Company: * BERLEX
Category: Diagnostic Aid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Magnevist Overview

Gadopentetic acid, sold under the brand name Magnevist, is a gadolinium-based MRI contrast agent.[1] It is usually administered as a salt of a complex of gadolinium with DTPA (diethylenetriaminepentacetate) with the chemical formula A2[Gd(DTPA)(H2O)]; when cation A is the protonated form of the amino sugar meglumine the salt goes under the name "gadopentetate dimeglumine". It was described in 1981 by Hanns-Joachim Weinmann and colleagues [3] and introduced as t...

Read more Magnevist Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Magnevist Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 469.01mg/ml, 496.01mg/ml
  • Solution: 529mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Magnevist: (1 result)

Sorted by National Drug Code
  • 50419-188 Magnevist 469.01 mg/ml Intravenous Injection by Bayer Healthcare Pharmaceuticals Inc.

Other drugs which contain Gadopentetate or a similar ingredient: (1 result)